Altimmune’s Pemvidutide Reduces Heavy Drinking in Phase 2 Alcohol Use Disorder Trial
Altimmune’s investigational dual GLP-1/glucagon receptor agonist met its primary and key secondary endpoints in a mid-stage trial for alcohol…
Altimmune’s investigational dual GLP-1/glucagon receptor agonist met its primary and key secondary endpoints in a mid-stage trial for alcohol…